Abstract:Background and objective: The association between human intestinal microbes and disease is an emerging topic in microbiome research, with potential implications in cancer diagnosis. Meanwhile, immune checkpoint inhibitor (ICI) therapy has been extensively applied to cancer patients but with relatively low overall response rate owing to pathological complexity. Thus, accurate prediction of cancer onset as well as patients' response to ICI treatment through non-invasive methods, such as gut microbiome profiling, could greatly facilitate cancer diagnosis and treatment practice, which essentially improves patients' quality of life. With the rapid accumulation of microbiome sequencing data and advanced machine learning algorithms, the use of gut microbiome as predictive biomarkers presents a feasible approach to address these problems. Methods and results: The first model we built is a predictive model for classifying healthy people from patients with colon cancer (CRC). The data (originated from Curated Metagenomics Data of Human Microbiome) consists of 166 fecal samples from healthy population and equal number of CRC patients from two studies (PRJEB24748, PRJEB6070). The data were divided into training and testing sets with a 3:1 ratio. Using the training dataset, we developed a Gradient Boosting Decision Tree model. To demonstrate the model's generalizability, we evaluated it using the testing dataset and the model achieved an AUC score of 0.93 (accuracy: 89%). Moreover, using an external independent cohort (which included 52 CRC patients from PRJEB12449 and 52 healthy individuals), we obtained an AUC score of 0.94 (accuracy: 88%). We also detected bacteria highly related to CRC pathology including Solobacterium_moorei, which could be potential biomarkers for CRC diagnosis. In addition, to predict CRC patients' response to ICI, we built a random forest model based on patients' fecal microbiome data before the ICI treatment. In total, stool metagenomics data from 63 CRC patients were used, including 30 patients responding to ICI treatment and 33 non-responders. With five-fold cross-validation, we achieved training and testing AUC score of 0.89 and 0.72, respectively. With an external data with 11 CRC patients' samples, the classifier achieved an AUC of 0.78. Several microbial taxa were listed as important features contributing to the classification, e.g. Eubacterium hallii – a butyrate producer, which previously report to have a positive association with ICI clinical benefits. Conclusion: Using the non-invasive human gut microbiome data and advanced machine learning techniques, we present here two models with great performance to predict the occurrence of CRC and clinical response to ICI treatment in CRC patients. Similar strategy could be readily transferred to other cancer types to improve early diagnosis and patient stratification. Moreover, the microbial taxa identified to be essential features in the model could be developed as potential therapeutic targets. Citation Format: Die Dai, Xiaomin Xu, Wei Shen, Zhengnong Zhu, Fang Li, Xiaochen Yin, Yan Kou. Gut microbiome as a promising biomarker for colorectal cancer diagnosis and immunotherapy response prediction [abstract]. In: Proceedings of the AACR Special Conference on Colorectal Cancer; 2022 Oct 1-4; Portland, OR. Philadelphia (PA): AACR; Cancer Res 2022;82(23 Suppl_1) nr A030.

CAT: a conditional association test for microbiome data using a leave-out approach

Multimiat: an Optimal Microbiome-Based Association Test for Multicategory Phenotypes

A Small-Sample Multivariate Kernel Machine Test for Microbiome Association Studies

A Powerful Adaptive Microbiome-Based Association Test for Microbial Association Signals with Diverse Sparsity Levels

Correlation and association analyses in microbiome study integrating multiomics in health and disease

An Adaptive Independence Test for Microbiome Community Data.

Strategy for an Association Study of the Intestinal Microbiome and Brain Metabolome Across the Lifespan of Rats.

Phylogenetic association analysis with conditional rank correlation

Phylogeny-guided microbiome OTU-specific association test (POST)

Powerful and robust non-parametric association testing for microbiome data via a zero-inflated quantile approach (ZINQ)

Detecting Sparse Microbial Association Signals Adaptively from Longitudinal Microbiome Data Based on Generalized Estimating Equations

A maximum-type microbial differential abundance test with application to high-dimensional microbiome data analyses

A Rarefaction-Based Extension of the LDM for Testing Presence-Absence Associations in the Microbiome

Regression-based Approach for Testing the Association Between Multi-Region Haplotype Configuration and Complex Trait

A Model-free Approach for Testing Association

A Novel Approach Based on KATZ Measure to Predict Associations of Human Microbiota with Non-Infectious Diseases

Transformation and differential abundance analysis of microbiome data incorporating phylogeny

Comparison of Statistical Testing and Predictive Analysis Methods for Feature Selection in Zero-inflated Microbiome Data

Abstract A030: Gut microbiome as a promising biomarker for colorectal cancer diagnosis and immunotherapy response prediction

Compositional Differential Abundance Testing: Defining and Finding a New Type of Health-Microbiome Associations

MCHMDA:Predicting Microbe-Disease Associations Based on Similarities and Low-Rank Matrix Completion